Healthcare Professionals

About Oral Mucositis

About Caphosol®

How to use Caphosol®

Further Information

Product Information

Clinical Experience

Economics (£ $ € zł)

Other Caphosol® Sites

Estimated Saving Per Patient of 0

Caphosol® costs are a small percentage of an entire cancer treatment yet prophylatic use from the start of therapy may result in significant additional overall savings as:

Caphosol® reduces the severity of OM grade 3–4 OM: 33% №
Caphosol® reduces the severity of grade 4 OM: 19% №
Caphosol® reduces requirement for feeding tubes: 24% №
Caphosol® reduces OM-related hospitalisation: 19% №

The percentages above show that Caphosol® can achieve significant reductions in the number of patients experiencing Oral Mucositis, and consequently may reduce the hospitalisation, drug, hcp, and other costs associated with the treatment. To arrive at the estimated saving we initially model our own data for Grade 3-4 OM only, using the table below you can replace our assumptions № with your own and press TAB or ENTER to see your savings further down the page.

Use our Head and Neck assumptions, or enter your own here:
Use the model for this therapy:	Head and NeckHead and Neck + PEGBMTBreastColon
Use initial data as estimated for:	EuropeUnited Kingdom€ EURO £ Sterling$ DollarsLow UK Daily CostAvg. UK Daily CostHigh UK Daily Cost
How many patients are undergoing therapy?
How many days of therapy?
Cost per Hospital day for OM evoked treatment?
Cost per dose of Caphosol®

Cost of PEG per patient/day?
Number of days with PEG?
Number of days hospitalisation for PEG placement?

Caphosol® has been shown to have an impact on the incidence and severity of OM with lower rates noted in both chemotherapy and radiation patients at high risk of developing OM. By using Caphosol® to reduce the incidence and severity of OM as an integral part of cancer therapy, resources and costs will be significantly reduced.  №

Caphosol® can save patients from problems caused by Oral Mucositis
Patients undergoing Cancer Therapy	0
Patients saved from Grade 3 and 4 OM with Caphosol®	0
Patients saved from Hospitalisation with Caphosol®	0

Patients saved from PEG tube need with Caphosol®

0

The consequences of OM include increased hospitalisations, more frequent and longer use of analgesics, anti-infectives and liquid diets, IV hydration and/or TPN, and interruption of the cancer therapy. Management of OM adds significantly to the overall cost of the individual cancer therapy. №

Caphosol® can save hospital costs that result from OM complications
Reduction in hospitalisation for OM with Caphosol®	0

Cost reduction of PEG with Caphosol®	0
Cost reduction with Caphosol® in H&N	0

Cost of Caphosol® in Therapy	0
Total cost savings by using Caphosol® from the start of therapy to reduce OM complications№	0
Cost Reduction per Patient	0

The fine detail that supports the calculated reductions:

H
Number of Patients undergoing cancer therapy	0
Incidence of grade 3 and 4 OM without Caphosol®№	0
Number of patients with grade 3 and 4 OM without Caphosol®	0
Incidence of grade 3 and 4 OM with Caphosol®№	0
Number of patients with grade 3 and 4 OM with Caphosol®	0
Patients NOT on Caphosol® requiring hospitalisation№	0
Number patients NOT on Caphosol® requiring hospitalisation	0
Patients ON Caphosol® requiring hospitalisation№	0
Number patients ON Caphosol® requiring hospitalisation	0
Number patients saved from hospitalisation by Caphosol® use	0

PEG:
% of patients NOT on Caphosol® that require PEG	0
Number of patients NOT on Caphosol® that require PEG	0
% of patients ON Caphosol® that require PEG	0
Number of patients ON Caphosol® that require PEG	0
Number of patients saved from PEG with Caphosol® use	0
Cost of PEG per patient per day	0
Number of days with PEG	0
Total cost of PEG per patient	0
Extra Costs for OM NOT on Caphosol® that require hospitalisation	0
Extra Costs for OM ON Caphosol® that require hospitalisation	0
Number of days hospitalisation prior to PEG placement	0
Cost of patients NOT on Caphosol® that require PEG	0
Cost of patients ON Caphosol® that require PEG	0
Total hospitalisation costs for PEG population	0

Mean number of treatment cycles	0
Mean additional length of hospital stay for OM patients№	0
Cost per additional OM evoked hospital day	0
Extra cost for hospitalised patients NOT on Caphosol®	0
Extra cost for hospitalised patients ON Caphosol®	0
COST REDUCTION with Caphosol® excluding Caphosol® supply	0
Number of Caphosol® administrations per day№	0
Duration of treatment in days	0
Total number of Caphosol® Days	0
Cost per Dose	0
TOTAL COST of Caphosol® Treatment	0
TOTAL COST REDUCTION№	0
TOTAL COST REDUCTION per Patient	0

---

To receive an electronic copy of your model which includes the itemised detail behind these Caphosol® savings please enter your email address in the space below and we will immediately send you a copy and have a customer service representative follow up to ensure all is clear with the data. (We will only use your email address specifically for the purposes stated here) You can also contact our customer services team directly on 01438 735751.

We can email you the detailed electronic copy of the model as shown, simply enter your email address in the space provided and we will send it immediately. (We will only use your email address specifically for the purpose stated here)

Email address:

Optional Details and any requests: EMail me a copy of my analysis

This is a modelling system and whilst we have used our best endeavours to ensure all calculations and data are correct, the savings and reductions are all hypothetical, intended as a general indication and are not guaranteed. Produced on "7/30/2010 2:25:50 AM using EM2-CAP/EUR/020/0809-02. This document is dynamic, electronic content and therefore technically "uncontrolled if printed".

References and other information within the text are indicated by the symbol № and are displayed when the mouse is positioned over the symbol.